Home Cart Sign in  
Chemical Structure| 1380424-42-9 Chemical Structure| 1380424-42-9

Structure of KML29
CAS No.: 1380424-42-9

Chemical Structure| 1380424-42-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KML29 is a highly selective and potent MAGL inhibitor with IC50s for 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KML29

CAS No. :1380424-42-9
Formula : C24H21F6NO7
M.W : 549.42
SMILES Code : O=C(N1CCC(C(C2=CC=C(OCO3)C3=C2)(C4=CC=C(OCO5)C5=C4)O)CC1)OC(C(F)(F)F)C(F)(F)F
MDL No. :MFCD22987957
InChI Key :SXHQLPHDBLTFPM-UHFFFAOYSA-N
Pubchem ID :71656212

Safety of KML29

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
KML29, known for its high selectivity, oral activity, and irreversible inhibition of MAGL, showcases IC50 values of 15 nM, 43 nM, and 5.9 nM for mouse, rat, and human MAGL respectively. This inhibitor has minimal cross-reactivity towards other central and peripheral serine hydrolases, including an absence of detectable activity against FAAH[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
rat cortical primary neurons 250 nM from DIV6 to DIV12, every 48 hours To evaluate the effect of MAGL inhibition on neuronal survival. KML29 significantly increased the risk of neuronal death in neuron-enriched cultures lacking glial cells, while neuronal survival was unaffected in mixed cultures (containing glial cells). Biomolecules. 2020 Aug 18;10(8):1198
PL neurons 100nM 10 minutes KML29 augmented evoked excitatory neurotransmission as evidenced by a left-shift in fEPSP I/O curve, and decreased sIPSC amplitude. KML29 also altered intrinsic properties of PL neurons including depolarization of resting membrane potential, decreased membrane time constant and decreased instantaneous frequency. Neuropharmacology. 2020 Apr;166:107964

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Ischemic injury model Intravenous injection 1 mg/kg Once daily for three days To evaluate the neuroprotective effects of KML29 in an ischemic injury model. Results showed that KML29 treatment significantly improved neuronal protection in the striatum and reduced neuroinflammation. Theranostics. 2021 Sep 13;11(19):9492-9502
C57BL/6 J mice Chronic constriction injury (CCI) model of neuropathic pain Intraperitoneal injection 1–40 mg/kg Once daily for 7 days To evaluate the analgesic effects of KML29 in combination with gabapentin. Results showed that low-dose KML29 combined with gabapentin additively attenuated mechanical allodynia and synergistically reduced cold allodynia without inducing tolerance. Br J Pharmacol. 2017 Dec;174(23):4523-4539
Mice Inflammatory and neuropathic pain models Intraperitoneal injection 40 mg·kg−1 Single or repeated administration KML29 significantly attenuated carrageenan-induced paw oedema and completely reversed carrageenan-induced mechanical allodynia. These effects underwent tolerance after repeated administration of high-dose KML29, which were accompanied by CB1 receptor desensitization. KML29 partially reversed allodynia in the sciatic nerve injury model and completely prevented diclofenac-induced gastric haemorrhages. Br J Pharmacol. 2014 Mar;171(6):1392-407
Rats Predator-induced fear model Intraperitoneal injection 4 and 16 mg/kg Single administration, 4 hours before testing KML29 produced a dose-dependent anxiolytic-like effect in TMT-exposed rats, increasing open arm time and reducing the anxiety index. Neuropsychopharmacology. 2020 Jul;45(8):1330-1338
Male Wistar rats Monoiodoacetate (MIA)-induced osteoarthritis pain model Intra-articular injection 700 μg/50μl Single administration, observed for 240 minutes To evaluate the effect of KML29 on MIA-induced secondary allodynia. Results showed that KML29 significantly improved the hindpaw withdrawal threshold, and this analgesic effect was blocked by CB1R and CB2R antagonists. Arthritis Res Ther. 2020 Jan 14;22(1):9
Mice Normotensive murine model Topical application 1 mM Measured at 1, 4, and 8 hours post-treatment KML29 lowers IOP in a CB1 receptor-dependent manner Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3287-96
Rats Object recognition task Bilateral intra-CA1 hippocampal injections 2 ng or 20 ng Immediately after training, tested 1 hr later KML29 abolished the impairing effects of stress on short-term memory, improving short-term recognition memory performance Int J Mol Sci. 2020 Oct 3;21(19):7316
Rat Healthy rats In vitro 1 µM 1 hour KML29 significantly reduced MAGL activity, by 92% in TG, 88% in cDRG, 86% in tDRG, and 93% in lDRG. Int J Mol Sci. 2021 Jan 26;22(3):1204
Male Fischer-344 rats Uncontrollable stress model Intra-vmPFC and intraperitoneal injection 200ng/0.5μL/hemisphere (intra-vmPFC), 40mg/kg (i.p.) Single administration Intra-vmPFC administration of KML29 prior to stress prevented stress-induced anxiety, while systemic administration of KML29 exacerbated stress-induced anxiety. Neuropharmacology. 2020 Apr;166:107964
Mice Acute N-methyl-D-aspartate (NMDA) receptor hypofunction model Intraperitoneal injection 1, 5, 20, 40 mg/kg Single administration To evaluate the impact of KML-29 on long-term memory in mice, results showed that KML-29 significantly increased the LI values for memory acquisition at the highest dose (40 mg/kg), and at the two highest doses (20 and 40 mg/kg) for memory consolidation and retrieval stages. Int J Mol Sci. 2023 Jul 13;24(14):11400

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.82mL

0.36mL

0.18mL

9.10mL

1.82mL

0.91mL

18.20mL

3.64mL

1.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories